Pyrotinib racemate is a racemic mixture of pyrotinib, serving as an irreversible dual tyrosine kinase inhibitor targeting HER2 and EGFR receptors. It is primarily utilized in pharmaceutical research and development for oncology applications, particularly in studying and treating HER2-positive breast cancer and other HER2-overexpressing malignancies. By blocking these receptors, it inhibits cancer cell proliferation. This compound is valuable as a research reagent, intermediate, or reference standard in drug discovery, with applications for patients resistant to prior HER2 therapies. Purity ≥97% ensures its suitability for laboratory and synthetic use.